Publications by authors named "J Reynes"

Background: We studied the duration of HPV detection and risk of (re-) detection for 25 HPV genotypes in a cohort of 132 women followed every eight weeks for up to two years between 2016 and 2020. Participants were between 18 and 25 years old at inclusion and half of them were vaccinated against HPV. They were recruited near the University and the STI detection centre in Montpellier, France.

View Article and Find Full Text PDF

In recent years, mechanochemistry has become an innovative and sustainable alternative to traditional solvent-based synthesis. Mechanochemistry rapidly expanded across a wide range of chemistry fields, including diverse organic compounds and active pharmaceutical ingredients, coordination compounds, organometallic complexes, main group frameworks, and technologically relevant materials. This Review aims to highlight recent advancements and accomplishments in mechanochemistry, underscoring its potential as a viable and eco-friendly alternative to conventional solution-based methods in the field of synthetic chemistry.

View Article and Find Full Text PDF

Background: Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance. We investigated a switch from bictegravir, emtricitabine, and tenofovir alafenamide to doravirine (100 mg) and islatravir (0·75 mg) in virologically suppressed adults with HIV-1.

Methods: We conducted a phase 3, multicentre, randomised, active-controlled, double-blind, double-dummy, non-inferiority trial at 89 research, community, and hospital-based clinics in 11 countries.

View Article and Find Full Text PDF

Background: People living with HIV (PLWH) are at risk of frailty, which is predictive for death. As an overactivity of the immune system is thought to fuel frailty, we characterized the immune activation profiles linked to frailty.

Methods: We quantified twenty-seven activation markers in forty-six virological responders (four females and forty-two males; median age, 74 years; median duration of infection, 24 years; median duration of undetectability, 13 years), whose frailty was determined according to the Fried criteria.

View Article and Find Full Text PDF
Article Synopsis
  • The NAMSAL-ANRS-12313 trial compared the efficacy of dolutegravir (DTG) versus efavirenz (EFV400) in treating HIV in low-income countries over a 96-week period, demonstrating DTG's noninferiority and continued effectiveness at 192 weeks.
  • At week 192, viral suppression remained higher in participants on the DTG regimen (69%) compared to those on EFV400 (62%), with slight differences in new viral failures and serious adverse events noted between the two groups.
  • Both treatment groups experienced significant weight gain, with participants on DTG/TDF/3TC gaining an average of 9.4 kg and an increase in obesity prevalence, raising concerns about
View Article and Find Full Text PDF